For GSK the failure comes at a time when it desperately needs Breo to gain momentum in order to offset a decline in sales of its predecessor Advair (fluticasone propionate/salmeterol), which saw ...
Meanwhile, sales of the products introduced to replace Advair/Seretide missed consensus estimates, with Breo (fluticasone furoate and vilanterol) bringing in £11 million and Anoro (umeclidinium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results